Home・Elenco Azioni・DexCom Inc

DexCom Inc

Chiusa

SettoreSettore sanitario

86.95 -0.29

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

85.87

Massimo

87.73

Metriche Chiave
By Trading Economics
Entrata	50M 249M
Vendite	117M 1.3B
P/E Media del settore	34.51 68.51
EPS	0.7
Margine di Profitto	19.039
Dipendenti	11,000
EBITDA	52M 389M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+3.68% upside

Dividendi
By Acuity
Utili prossimi	29 ott 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	4.6B 33B
Apertura precedente	87.24
Chiusura precedente	86.95

Notizie sul Sentiment di mercato

By Acuity

21%

79%

64 / 340 Classifica in Healthcare

DexCom Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 ago 2026, 19:56 UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

3 ago 2026, 20:02 UTC

News

Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

31 lug 2026, 20:04 UTC

News

Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

30 lug 2026, 23:51 UTC

News

Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

29 lug 2026, 23:41 UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

28 lug 2026, 20:06 UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

27 lug 2026, 19:06 UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

24 lug 2026, 15:22 UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

22 lug 2026, 20:01 UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

21 lug 2026, 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

20 lug 2026, 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Confronto tra pari

Modifica del prezzo

DexCom Inc Previsione

Obiettivo di Prezzo

By TipRanks

3.68% in crescita

Previsioni per 12 mesi

Media 90.52 USD 3.68%

Alto 112 USD

Basso 64 USD

Basato su 23 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per DexCom Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

23 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 23 che hanno fornito valutazioni azionarie a DexCom Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

64 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.